#USA #Nashville #Cumberland Pharmaceuticals #Chemotherapy #Sancuso

Announcing the New Sancuso® Website

Cumberland Pharmaceuticals Inc., a leading specialty pharmaceutical company based in Nashville, recently introduced its revamped website dedicated to Sancuso®, the first prescription transdermal patch designed to prevent nausea and vomiting associated with chemotherapy. This resource aims to offer patients and healthcare professionals better access to educational materials, practical insights, and clinical information for managing chemotherapy-induced nausea and vomiting (CINV).

The Sancuso patch stands out as a unique solution for patients undergoing chemotherapy. Delivering granisetron through the skin, this innovative product offers continuous relief for up to five days, representing a significant advancement over traditional oral antiemetic therapies. This is particularly valuable for patients who struggle with oral medications during their treatment.

Key Features of the New Sancuso® Website

The updated website provides comprehensive resources for both patients and healthcare providers:

1. Detailed Product Information: Users can find an in-depth overview of Sancuso, including clinical efficacy data, prescribing suggestions, and guidelines for patient usage specifically for CINV prevention.

2. Healthcare Provider Resources: These tools are crafted to assist oncologists and oncology care teams in effectively managing CINV, helping them understand the intricacies involved in patient care during chemotherapy.

3. Expert Insights from Dr. Ehsan: The website features a special section with insights from Dr. Ehsan, an experienced oncologist, which provides practical tips and clinical guidance regarding CINV management and antiemetic therapy. This resource aims to bridge the knowledge gap for healthcare providers actively working with chemotherapy patients.

4. Patient Education Materials: Recognizing the importance of informed patients, the site offers educational content that helps patients comprehend the symptoms of chemotherapy-related nausea and vomiting, along with available treatment options.

5. User-Friendly Experience: The website has been designed for easy navigation, tailored for mobile devices to ensure that users can swiftly find relevant information.

Understanding the Importance of Sancuso®

Sancuso represents a pivotal innovation in oncology, being the only FDA-approved transdermal patch specifically authorized for the prevention of CINV in patients receiving moderately and/or highly emetogenic chemotherapy. Applied before chemotherapy sessions, the patch consistently releases medication into the bloodstream via the skin, providing a reliable preventive measure against nausea and vomiting for regimens lasting up to five days.

Healthcare professionals and patients interested in exploring these resources can visit the new Sancuso website at www.sancuso.com, where all prescribing and safety information is also available.

About Cumberland Pharmaceuticals

Founded in Tennessee, Cumberland Pharmaceuticals Inc. focuses on enhancing patient care through innovative biopharmaceuticals. In addition to Sancuso, their portfolio includes other FDA-approved products designed to meet various acute care, gastroenterology, and oncology needs, such as Acetadote® for acetaminophen poisoning and Kristalose® for treating constipation.

Cumberland Pharmaceuticals is committed to developing unique solutions for hospitals and continuing its mission to support patients and healthcare professionals alike in navigating the complexities of medical treatment. With its recent initiatives, Cumberland underscores its dedication to improving the quality of life for those undergoing challenging treatments like chemotherapy.

For more insights into their ongoing projects, including clinical trials related to cardiomyopathy, the company encourages you to keep an eye on their developments in the sector, ensuring that they continuously spearhead advancements in pharmaceuticals.

In summary, the launch of the new Sancuso website marks an important step in facilitating better communication and access to vital information for patients undergoing chemotherapy, reinforcing Cumberland Pharmaceuticals’ role as a key player in the pharmaceutical industry.